Recombinant collagenase - Connext
Alternative Names: CNT-201; CNT-202Latest Information Update: 19 Aug 2026
At a glance
- Originator Connext
- Class Collagenases; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Collagenase replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cellulite; Dupuytren's contracture; Peyronie's disease; Wounds
Highest Development Phases
- Phase I/II Dupuytren's contracture
- Phase I Cellulite; Peyronie's disease
- Preclinical Wounds
Most Recent Events
- 17 Aug 2026 Recombinant collagenase is still in preclinical phase for Wounds in South Korea (Parenteral) (Connext pipeline; August 2026)
- 17 Aug 2026 Phase-I clinical trials in Cellulite (Parenteral) prior to August 2026 (Connext pipeline, August 2026)
- 17 Aug 2026 Phase-I clinical trials in Peyronie's disease (Parenteral) prior to August 2026 (Connext pipeline, August 2026)